Short answer · Medically reviewed summary · Last updated: 2026-05-08
Chordoma is classified under the ICD-10-CM code C41.2 (Malignant neoplasm of vertebral column) or C41.4 (Malignant neoplasm of pelvic bones, sacrum, coccyx), depending on the tumor location, while the ICD-9-CM code is 170.2 or 170.6. Because Chordoma is a rare, slow-growing bone cancer arising from notochord remnants, accurate coding is essential for medical billing and tracking the longitudinal health outcomes of the 34 members currently sharing their experiences on DiseaseMaps.org. What is the clinical nature of Chordoma? Chordoma is a rare type of cancer that occurs in the bones of the skull base and the spine.
ICD10 code of Chordoma and ICD9 code
ICD-10 and ICD-9 codes for Chordoma, with classification details for clinicians, coders and patients.
Chordoma is classified under the ICD-10-CM code C41.2 (Malignant neoplasm of vertebral column) or C41.4 (Malignant neoplasm of pelvic bones, sacrum, coccyx), depending on the tumor location, while the ICD-9-CM code is 170.2 or 170.6. Because Chordoma is a rare, slow-growing bone cancer arising from notochord remnants, accurate coding is essential for medical billing and tracking the longitudinal health outcomes of the 34 members currently sharing their experiences on DiseaseMaps.org.
What is the clinical nature of Chordoma?
Chordoma is a rare type of cancer that occurs in the bones of the skull base and the spine. It is a slow-growing but locally aggressive tumor. Because Chordoma is often resistant to conventional chemotherapy, treatment typically involves complex surgery followed by specialized radiation therapy, such as proton beam therapy, to target the tumor while sparing adjacent neural structures.
How is Chordoma diagnosed and classified?
Diagnosis of Chordoma typically requires a combination of high-resolution imaging (MRI or CT scans) and a biopsy for histological confirmation. Pathologists identify Chordoma cells by their characteristic "physaliferous" appearance and the expression of the protein brachyury. Clinicians use specific staging systems to determine the extent of the disease, which helps in selecting the most appropriate surgical approach.
What are the key facts about Chordoma prevalence?
Understanding the epidemiology of Chordoma is vital for research and patient advocacy. Key facts include:
- Incidence: Approximately 0.08 to 0.5 per 100,000 people per year.
- Age of Onset: Most commonly diagnosed between 40 and 70 years of age, though it can occur at any age.
- Distribution: Roughly 50% of cases arise in the sacrococcygeal region, 35% in the skull base, and 15% in the mobile spine.
Next steps
- Consult with a neuro-oncologist or an orthopedic oncologist specializing in Chordoma treatment at a major academic medical center.
- Connect with the 34 members of the DiseaseMaps.org Chordoma community to share insights on managing long-term follow-up care.
- Review clinical trial databases (such as ClinicalTrials.gov) to see if you are eligible for emerging targeted therapies.
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment from your healthcare provider.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Chordoma.
- Orphanet: Rare disease database, entry for Chordoma (ORPHA:187).
- Chordoma Foundation: Patient resources and clinical research updates.
- National Cancer Institute (NCI): Surveillance, Epidemiology, and End Results (SEER) Program.
